There are currently 227 clinical trials in Augusta, Georgia looking for participants to engage in research studies. Trials are conducted at various facilities, including Augusta University, Augusta University Medical Center, Medical College of Georgia and Georgia Regents University. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
Human Milk in Preterm Infants
Recruiting
Current NICU protocol introduces human milk fortifier at 8 days of feeding. This study will introduce human milk fortifier at day 1. The primary outcome is the effect on growth velocity at 28 days and 36 weeks post menstrual age.
Gender:
All
Ages:
4 days and below
Trial Updated:
07/19/2022
Locations: Children's Hospital of Georgia, Augusta, Georgia
Conditions: Preterm Birth
Translumbosacral Neuromodulation for FI
Recruiting
Fecal Incontinence (FI) affects 40 million Americans, predominantly women and elderly. It is a major health care burden, significantly impairs quality of life and psychosocial function. FI is characterized by multifactorial dysfunction including lumbosacral neuropathy, anorectal sensori-motor dysfunction, and abnormal pelvic floor-brain innervation. A critical barrier to progress in the treatment of FI is the lack of RCTs, absence of mechanistically based non-invasive therapies that modify disea... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
07/19/2022
Locations: Augusta University, Augusta, Georgia
Conditions: Fecal Incontinence
Thoracic Neuromodulation for Diabetic Gastroparesis
Recruiting
The global incidence of diabetes is rising. Gastroparesis is a significant complication of diabetes that results in debilitating symptoms and affects quality of life. Current treatment options for diabetic gastroparesis are limited. Significant visceral afferent neuropathy is associated with diabetic gastroparesis and sympathetic overactivity is seen in nausea, both type 1 and 2 diabetes, and diabetic complications. These dysfunctions can result from neuropathy affecting the thoracic spinal nerv... Read More
Gender:
All
Ages:
Between 18 years and 85 years
Trial Updated:
06/29/2022
Locations: Augusta University, Augusta, Georgia
Conditions: Diabetic Gastroparesis
Dipraglurant (ADX48621) for the Treatment of Patients With Parkinson's Disease Receiving Levodopa-based Therapy
Recruiting
This study is designed to evaluate the safety and efficacy of dipraglurant in PD patients with dyskinesia (randomized 1:1 to receive active or placebo) for 12 weeks (1 week at 150 mg per day and 11 weeks at 300 mg per day). The primary efficacy assessment will be based on the Unified Dyskinesia Rating Scale (UDysRS). Patients who complete the 12-week blinded treatment period may have the option to roll into an open-label safety extension study for an additional 12-month treatment period.
Gender:
All
Ages:
Between 30 years and 85 years
Trial Updated:
05/18/2022
Locations: Augusta University, Augusta, Georgia
Conditions: Parkinson Disease, Dyskinesia, Drug-Induced, Dyskinesias
Open-label Safety Study of Dipraglurant (ADX48621) in Patients With Parkinson's Disease Receiving Levodopa-based Therapy
Recruiting
This open-label study is designed to assess the long-term safety and tolerability of dipraglurant in PD patients for up to 52 weeks (at doses of 150-300 mg per day) for patients that have completed an Addex sponsored double-blind clinical trial of dipraglurant.
Gender:
All
Ages:
Between 30 years and 85 years
Trial Updated:
04/18/2022
Locations: Augusta University, Augusta, Georgia
Conditions: Parkinson Disease, Dyskinesia, Drug-Induced, Dyskinesias
IBP-9414 for the Prevention of Necrotizing Enterocolitis - The Connection Study
Recruiting
IBP-9414 will be evaluated in preterm infants with a birth weight of 500-1500g, compared to placebo with regards to efficacy and safety in the prevention of necrotizing enterocolitis.
Gender:
All
Ages:
48 hours and below
Trial Updated:
03/08/2022
Locations: Georgia Regents University, Augusta, Georgia
Conditions: Necrotizing Enterocolitis
KRT-232 and TKI Study in Chronic Myeloid Leukemia
Recruiting
This study evaluates KRT-232, a novel oral small molecule inhibitor of MDM2, for the treatment of patients with Ph+ Chronic Myeloid Leukemia (CML) who have relapsed or are refractory or intolerant to a Tyrosine Kinase Inhibitor (TKI). This study is a global, open label Phase 1b/2 to determine the efficacy and safety of KRT-232 in patients with chronic phase CML (CML-CP) and accelerated phase (CML-AP) who have failed TKI treatments.
Gender:
All
Ages:
18 years and above
Trial Updated:
03/04/2022
Locations: Georgia Cancer Center at Augusta University, Augusta, Georgia
Conditions: Chronic Myeloid Leukemia
Compliance With Enhanced Recovery After Surgery Protocol (ERAS) in Surgical Patients
Recruiting
The concept of "enhanced recovery" was introduced by European anesthesiologists and surgeons who challenged traditional clinical practices involved in peri-operative care in 1990s. The goal of enhanced recovery programs (ERP) is to maintain normal physiology thereby decreasing complications. It focuses on peri-operative optimization of patient care. It was originally created for open colorectal surgeries but now has shown benefit in various surgical specialities including thoracic surgery, vascu... Read More
Gender:
Female
Ages:
18 years and above
Trial Updated:
02/14/2022
Locations: Augusta University, Augusta, Georgia
Conditions: Surgery, Anesthesia
MultiStem® Administration for Stroke Treatment and Enhanced Recovery Study
Recruiting
A Phase 3 study to examine the safety and effectiveness of the allogeneic, adult stem cell investigational product, MultiStem, in adults who have suffered an acute ischemic stroke in the previous 18-36 hours.
Gender:
All
Ages:
18 years and above
Trial Updated:
02/08/2022
Locations: Athersys Investigational Site 103, Augusta, Georgia
Conditions: Ischemic Stroke
Salt and Gut Study
Recruiting
High sodium intake is a significant risk factor for hypertension. Recently, animal studies connect high sodium intake to the gut-immune axis and highlight the gut microbiome as a potential therapeutic target to counteract salt-sensitive conditions and hypertension. The objective of this project is to determine the effects of high salt intake on gut microbiota composition and gut intestine barrier integrity, leading to increased BP in humans. The investigators also hypothesize that high salt inta... Read More
Gender:
All
Ages:
Between 18 years and 50 years
Trial Updated:
06/29/2021
Locations: Georgia Prevention Institute/ Augusta University, Augusta, Georgia
Conditions: High Blood Pressure
Thoracic Splanchnic Magnetic Neuromodulation Therapy (ThorS-MagNT) for Grade 3 Diabetic Gastroparesis: Pilot Study
Recruiting
Diabetic gastroparesis (DG) is an under recognized and significant complication of diabetes with lack of effective treatments. Recently, a 4-fold increase in hospitalizations has been seen in DG patients with refractory symptoms, defined as Grade 3 gastroparesis. A critical barrier to progress has been both a lack of pathophysiological understanding of DG and absence of effective treatments. Diabetic autonomic neuropathy is felt to be a key dysfunction in DG that causes gastric atony and segment... Read More
Gender:
All
Ages:
Between 18 years and 85 years
Trial Updated:
01/25/2021
Locations: Augusta University, Augusta, Georgia
Conditions: Diabetic Gastroparesis